MRD Tied to Allo-Transplant Benefit in NPM1-Mutated Acute Myeloid Leukemia
SAN DIEGO — Measurable residual disease (MRD) after induction therapy can guide the use of allogeneic transplant in patients with NPM1-mutated acute myeloid leukemia (AML) in first remission, regardless of whether FLT3 internal tandem duplication (ITD) mutations are present as well, according to an analysis of two randomized trials. Of more than 700 patients in […]